I disagree.
FDA approval is a long and windy road that most pharma plays don't ever get. However, BOT has. That is a huge issue with taking drugs to market.
Now, phase 2 results are wrapping up.
Without saying the curse word too many times, a T/O is very common for bio plays that have validated their product in humans and can highlight the mechanism of action. Why? Big pharma plays will swallow any start-up with these checks. The money to be made for them and the resources they can chuck at a product that works is exponential.
I don't think all are holding BOT hoping for it to reach market, but rather a buy-out based on positive phase 2 results.
Lest we forget, there are multiple products here ....
These are just my thoughts.
Bot Chart, page-995
-
- There are more pages in this discussion • 12,865 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.0¢ | $3.051M | 8.277M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 465836 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 301865 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |